Differential Effects of MS Therapeutics on B Cells—Implications for Their Use and Failure in AQP4-Positive NMOSD Patients

B cells are considered major contributors to multiple sclerosis (MS) pathophysiology. While lately approved disease-modifying drugs like ocrelizumab deplete B cells directly, most MS medications were not primarily designed to target B cells. Here, we review the current understanding how approved MS...

Descripción completa

Detalles Bibliográficos
Autores principales: Traub, Jan, Häusser-Kinzel, Silke, Weber, Martin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404039/
https://www.ncbi.nlm.nih.gov/pubmed/32708663
http://dx.doi.org/10.3390/ijms21145021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404039/
https://www.ncbi.nlm.nih.gov/pubmed/32708663
http://dx.doi.org/10.3390/ijms21145021

Ejemplares similares